Eli Lilly
3/10
Eli Lilly carries $29.5B in long-term debt, with $8.3B in scheduled principal maturities. Notably, the entire $8.3B maturity schedule falls within five years, creating a concentrated refinancing window. DebtCanary scores LLY at 3/10, suggesting manageable refinancing risk.
Maturity Schedule
| Period | Amount Due |
|---|---|
| Year 1 (0-12 months) | $781M |
| Year 2 (12-24 months) | $1.5B |
| Year 3 (24-36 months) | $2.5B |
| Year 4 (36-48 months) | $442M |
| Year 5 (48-60 months) | $3.1B |
| Beyond 5 Years | N/A |
| Total Scheduled Maturities | $8.3B |
Key Metrics
Score Components
| Component | Value |
|---|---|
| Near-Term Maturity Concentration | 9.4% |
| Interest Coverage Ratio | N/A |
| Debt-to-Equity Ratio | 1.11 |
| Cash Coverage of Near-Term Debt | 9.31x |
Recent SEC Filings
Material disclosures from Eli Lilly's most recent EDGAR filings. 8-K item labels indicate the type of event reported.
Related Companies
Data Source:
Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports).
Fiscal period end: 2025-12-31.
Filing date: 2026-02-12.
Data last fetched: 2026-04-29.
Maturity schedules reflect the company's most recently reported debt repayment obligations.
Data quality: Partial.
View SEC EDGAR filings for Eli Lilly →